CERE - Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
- Cerevel Therapeutics press release ( NASDAQ: CERE ): Q2 GAAP EPS of -$0.61 misses by $0.13 .
- Cash, cash equivalents and marketable securities as of June 30, 2022, were $531.2 million, inclusive of $37.5M from the tavapadon risk-sharing arrangement received in April 2022.
For further details see:
Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13